ClinicalTrials.gg
TerminatedNCT02768558Updated Jun 2, 2021Results posted

Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC

A Phase 3 interventional study of Radiation Therapy (RT) and Cisplatin in Non-Small Cell Lung Cancer, sponsored by RTOG Foundation, Inc.. Terminated at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-02.

Sponsored by RTOG Foundation, Inc. · Phase 3, Interventional, and Treatment

How we know · 7 judgments

Why this study was terminated
Another treatment found efficacious

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 43 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
93rd of 120
20 · median 66
Started
2016
with 6 others
Phase 3
24 of 120
3 open now
Registered
28th of 120
by date

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 93rd largest by enrollment, is one of 7 that started in 2016, is one of 24 in phase 3, and was the 28th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Patients with Stage III unresectable non-small cell lung cancer will receive thoracic radiation, cisplatin and etoposide followed by nivolumab or placebo given every 2 weeks for a year.

Read the detailed description

PRIMARY OBJECTIVES:

I. To compare the Overall Survival (OS) for patients with Stage III unresectable non-small cell lung cancer treated with or without nivolumab following concurrent chemoradiation.

II. To compare Progression-Free Survival (PFS) according to RECIST 1.1 criteria for patients with Stage III unresectable non-small cell lung cancer treated with or without nivolumab following concurrent chemoradiation.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Lung Cancer
  • NSCLC
  • Nivolumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathologically (histologically or cytologically) proven diagnosis of non-small cell lung cancer (NSCLC) with unresectable, medically inoperable disease, or patients who refuse resection stage IIIA or stage IIIB disease (AJCC 7th edition)
  • History/physical examination within 30 days prior to registration
  • Computed tomography (CT) scan with IV contrast (CT scan without contrast acceptable if IV contrast is medically ) of the lung and upper abdomen through the adrenal glands within 60 days prior to registration (recommended within 30 days prior to registration)
  • Magnetic resonance imaging (MRI) of the brain with contrast (or CT with contrast if MRI is medically contraindicated) within 60 days prior to registration; note: the use of intravenous contrast is required for the MRI or CT (unless medically contra-indicated).
  • Whole-body fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT within 60 days prior to registration; Note: patients do not need to have a separate CT of chest and upper abdomen with contrast if PET/CT imaging includes a high quality CT chest with contrast.
  • Age ≥ 18 years
  • The trial is open to both genders
  • Zubrod Performance status of 0-1
  • Forced Expiratory Volume at one second () > 1.2 liters; Diffusion Capacity of Lung for Carbon Monoxide (DLCO) ≥ 50% predicted
  • Patients must be at least 3 weeks from prior thoracotomy (if performed); if prior thoracotomy then on imaging must be present
  • Negative serum pregnancy test within three days prior to registration for women of
  • An archived tumor block or punches instead block must be available for submission for programmed death-ligand 1 () analysis. If an archived tumor block sample cannot be shipped for this study, then two 3mm punches from the core needle blocks may be provided for analysis. Note: core or excisional biopsy is required for this study. Fine needle aspirates (FNA) and cytology specimens are not adequate for PD-L1 analysis.
  • Agreement of women of childbearing potential to use highly effective during receipt of study drug and up to 161 days (23 weeks) from the last dose of nivolumab/placebo and men receiving nivolumab/placebo who are sexually active with women of childbearing potential to use highly effective contraception during receipt of study drug for 31 weeks from the last dose of nivolumab/placebo.

Exclusion criteria

Exclusion Criteria:

  • Definitive clinical or radiological evidence of disease
  • Prior or current invasive (except non-melanomatous skin cancer, localized bladder and prostate cancer) unless disease free for a minimum of 2 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
  • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields. For example, patients with prior breast radiotherapy treatments would likely be excluded.
  • Prior systemic treatment with and anti-programmed cell death protein 1 (PD1), , anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
  • Known disease, for example infection or history of bone marrow transplant or chronic lymphocytic leukemia (CLL)
  • (COPD) exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration. COPD requiring chronic oral therapy
  • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
  • Transmural myocardial infarction within the last 6 months
  • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
  • History of symptomatic or p previously established interstitial lung disease
  • Positive test for virus surface antigen (HBV sAg) or virus ribonucleic acid (HCV antibody) indicating acute or chronic infection;
  • History of severe reaction to any monoclonal antibody or allergy to study drug components
  • As there is potential for hepatic toxicity with nivolumab, drugs with a predisposition to hepatotoxicity should be used with caution in patients treated with nivolumab-containing regimen
  • Pregnancy, nursing females or women of and men who are sexually active and not willing/able to use medically acceptable forms of ; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Nivolumab

    60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by nivolumab

    Radiation: Radiation Therapy (RT) · Drug: Cisplatin · Drug: Etoposide · Drug: Nivolumab

  • Placebo comparator
    Placebo

    60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by placebo

    Radiation: Radiation Therapy (RT) · Drug: Cisplatin · Drug: Etoposide · Other: Placebo

Interventions

  • RadiationRadiation Therapy (RT)

    2 Gy fractions once a day, 5 days per week, for a total of 60 Gy in 30 fractions.

    Also known as: 3 Dimensional Conformal Radiation Therapy (3DCRT), Intensity Modulated Radiation Therapy (IMRT)

  • Concurrently with radiation therapy, 50 mg/m2, IV, on days 1, 8, 29, and 36, to begin with day 1 of radiation therapy.

    Also known as: Platinol

  • Concurrently with radiation, 40 mg/m2, IV, on days 1-5 and 29-33, to begin with day 1 of radiation therapy.

    Also known as: VP-16

  • Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.

    Also known as: Opdivo

  • OtherPlacebo

    Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Survival time is defined as time from registration to date of death from any cause and was to be estimated by the Kaplan-Meier method. Given the limited follow-up due to early closure and termination of data collection, only the number of patients last reported to be alive at time of study termination is reported and no statistical testing was done.

    Time frame: From registration to study termination. Maximum follow-up was 14.9 months.

  2. Progression-Free Survival (PFS)

    Progression is defined using the Response Evaluation Criteria In Solid Tumors Criteria (RECIST) guideline v1.1 as a 20% increase in the sum of the longest diameter of target lesions, a measurable increase in a non-target lesion, or the appearance of new lesions at any location. Progression was to be determined by an independent radiology review committee using scans submitted to a central location. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored) and was to be estimated by the Kaplan-Meier method.

    Time frame: From registration to study termination. Maximum follow-up was 14.9 months.

Secondary outcomes

  1. Number of Participants With Grade 3+ Adverse Events

    Adverse events (AE) are graded using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Grade refers to the severity of the AE. The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.

    Time frame: From registration to study termination. Maximum follow-up was 14.9 months.

  2. Percentage of Participants With Deterioration in Functional Assessment of Cancer Therapy - Trial Outcome Index for Lung Cancer (FACT-TOI) at 15 Months

    FACT-TOI is a measure of 21 items that sum the functional well being (FWB), physical well being (PWB), and the lung cancer subscale (LCS) of the Functional Assessment of Cancer Therapy - Lung (FACT-L) QOL instrument, used for measuring QOL in patients with lung cancer. All items are rated on a 5 item (point) Likert Scale, from 0 (not at all) to 4 (very much). FACT-TOI is scored by summing the individual scale scores, with higher scores indicating better quality of life. Deterioration was defined as a decrease of 5 points or more from baseline.

    Time frame: Baseline and 15 months

  3. Overall Survival by PD-L1 Status

    Time frame: From registration to study termination. Maximum follow-up was 14.9 months.

  4. Progression-Free Survival by PD-L1 Status

    Time frame: From registration to study termination. Maximum follow-up was 14.9 months.

07

Results

Posted Feb 25, 2020
Limitations and caveats
This study was terminated early due to the reporting of another study which changed this population's standard of care and rendered the control arm obsolete. Eight of the planned 550 analyzable participants were enrolled at the time of termination.

Participant flow

Participant flow — Overall Study
MilestoneNivolumabPlacebo
Started35
Eligible35
Completed35
Not completed00

Outcome measures

PrimaryOverall Survival (OS)

Survival time is defined as time from registration to date of death from any cause and was to be estimated by the Kaplan-Meier method. Given the limited follow-up due to early closure and termination of data collection, only the number of patients last reported to be alive at time of study termination is reported and no statistical testing was done.

Time frame:
From registration to study termination. Maximum follow-up was 14.9 months.
Reported as:
Count of participants · Participants
Overall Survival (OS)
ParticipantsNivolumabPlacebo
Overall Survival (OS)25
PrimaryProgression-Free Survival (PFS)

Progression is defined using the Response Evaluation Criteria In Solid Tumors Criteria (RECIST) guideline v1.1 as a 20% increase in the sum of the longest diameter of target lesions, a measurable increase in a non-target lesion, or the appearance of new lesions at any location. Progression was to be determined by an independent radiology review committee using scans submitted to a central location. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored) and was to be estimated by the Kaplan-Meier method.

Time frame:
From registration to study termination. Maximum follow-up was 14.9 months.

No measurements were reported for this outcome.

SecondaryNumber of Participants With Grade 3+ Adverse Events

Adverse events (AE) are graded using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Grade refers to the severity of the AE. The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.

Time frame:
From registration to study termination. Maximum follow-up was 14.9 months.
Reported as:
Count of participants · Participants
Number of Participants With Grade 3+ Adverse Events
ParticipantsNivolumabPlacebo
Number of Participants With Grade 3+ Adverse Events33
SecondaryPercentage of Participants With Deterioration in Functional Assessment of Cancer Therapy - Trial Outcome Index for Lung Cancer (FACT-TOI) at 15 Months

FACT-TOI is a measure of 21 items that sum the functional well being (FWB), physical well being (PWB), and the lung cancer subscale (LCS) of the Functional Assessment of Cancer Therapy - Lung (FACT-L) QOL instrument, used for measuring QOL in patients with lung cancer. All items are rated on a 5 item (point) Likert Scale, from 0 (not at all) to 4 (very much). FACT-TOI is scored by summing the individual scale scores, with higher scores indicating better quality of life. Deterioration was defined as a decrease of 5 points or more from baseline.

Time frame:
Baseline and 15 months

No measurements were reported for this outcome.

SecondaryOverall Survival by PD-L1 Status
Time frame:
From registration to study termination. Maximum follow-up was 14.9 months.

No measurements were reported for this outcome.

SecondaryProgression-Free Survival by PD-L1 Status
Time frame:
From registration to study termination. Maximum follow-up was 14.9 months.

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events were to be reported every 3 months until 2 years post-chemoradiation, then every 6 months until 5 years post-chemoradiation, then yearly until study termination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Placebo0/5 (0%)1/5 (20%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventNivolumabPlacebo
Febrile neutropeniaBlood and lymphatic system disorders1/31/5
Death NOSGeneral disorders1/30/5
Lung infectionInfections and infestations1/30/5
HypercalcemiaMetabolism and nutrition disorders1/30/5
HyperglycemiaMetabolism and nutrition disorders1/30/5
HypophosphatemiaMetabolism and nutrition disorders1/30/5
SyncopeNervous system disorders1/30/5
Acute kidney injuryRenal and urinary disorders1/30/5
Most frequent other events
Showing 10 of 79
Most frequent other events
EventNivolumabPlacebo
AnemiaBlood and lymphatic system disorders3/35/5
NauseaGastrointestinal disorders3/32/5
FatigueGeneral disorders3/35/5
Lymphocyte count decreasedInvestigations3/32/5
Platelet count decreasedInvestigations3/31/5
CoughRespiratory, thoracic and mediastinal disorders3/32/5
DysphagiaGastrointestinal disorders2/34/5
TinnitusEar and labyrinth disorders2/31/5
ConstipationGastrointestinal disorders2/33/5
EsophagitisGastrointestinal disorders2/32/5

Baseline characteristics

Eligible participants

Age, Continuous
Age, Continuous(years)NivolumabPlaceboTotal
Median72 (71 to 73)64 (57 to 69)67.5 (57 to 73)
Age, Customized
Age, Customized(Participants)NivolumabPlaceboTotal
50-59 years011
60-69 years044
≥ 70 years303
Sex: Female, Male
Sex: Female, Male(Participants)NivolumabPlaceboTotal
Female145
Male213
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NivolumabPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino358
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NivolumabPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White257
More than one race000
Unknown or Not Reported000
Zubrod Performance Status
Zubrod Performance Status(Participants)NivolumabPlaceboTotal
0011
1347
Histology
Histology(Participants)NivolumabPlaceboTotal
Adenocarcinoma235
Squamous cell carcinoma123
PD-L1
PD-L1(Participants)NivolumabPlaceboTotal
< 1%033
≥ 1%213
Not Evaluable112
08

Study locations

16 sites
  • UC San Diego Moores Cancer Center
    La Jolla, California 92093, United States
  • Stanford University
    Stanford, California 94305, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Mount Sinai Cancer Research Center
    Miami Beach, Florida 33140, United States
  • Nancy N. & J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler Hospital
    Savannah, Georgia 31405, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Mercy Medical Cancer Center
    Baltimore, Maryland 21202, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Metro Health Medical Center
    Cleveland, Ohio 44109, United States
  • Reading Hospital/McGlinn Cancer Institute
    West Reading, Pennsylvania 19611, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
  • Virginia Mason
    Seattle, Washington 98101, United States
  • University of Wisconsin Hospital and Clinics
    Madison, Wisconsin 53792, United States
09

References and documents

Publications

  • Gerber DE, Urbanic JJ, Langer C, Hu C, Chang IF, Lu B, Movsas B, Jeraj R, Curran WJ, Bradley JD. Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). Clin Lung Cancer. 2017 May;18(3):333-339. doi: 10.1016/j.cllc.2016.10.009. Epub 2016 Oct 26. PubMed 27923550 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2016 to primary completion in Jan 2019, 27 months.

Results were first posted in Feb 2020, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2016
First posted
May 11, 2016
StartActual
Oct 17, 2016
Primary completionActual
Jan 23, 2019
CompletionActual
Jan 23, 2019
Results first posted
Feb 25, 2020
Last update
Jun 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02768558
Lead sponsor
RTOG Foundation, Inc.
Responsible party
Sponsor
First posted
May 11, 2016
Start date
Oct 17, 2016
Primary completion
Jan 23, 2019
Completion
Jan 23, 2019
Results posted
Feb 25, 2020
Last update
Jun 2, 2021

Study contacts

David Gerber, MD
principal investigator · RTOG Foundation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion